An Open-Label, Multi-Center, Parallel and Sequential, Ascending Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 in Prostate Cancer Patients.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 23 Jun 2009 Trial phase changed from II/III to II as reported by ClinicalTrials.gov.
- 23 Jun 2009 Trial phase changed from II/III to II as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.